Novel agents to target treatment resistance in ovarian cancer

Christina R. Washington, Debra L. Richardson, Amma F. Agyemang, Kunle O. Odunsi, Kathleen N. Moore

Research output: Chapter in Book/Report/Conference proceedingChapter


Chemotherapy resistance is a common occurrence in women who have undergone treatment for epithelial ovarian cancer. Combination chemotherapy, while helpful in delaying the development of resistance, carries increased toxicity and a poorer safety profile. As a result, numerous studies are investigating additional pharmacological targets, combination therapies, and repurposed agents for ovarian cancer treatment. This chapter summarizes clinical studies investigating novel combination therapies and targeted treatments that may hold promise in future clinical applications.

Original languageEnglish (US)
Title of host publicationOvercoming Ovarian Cancer Chemoresistance
Number of pages21
ISBN (Electronic)9780128198407
ISBN (Print)9780128198414
StatePublished - Jan 1 2020
Externally publishedYes


  • Chemoresistance
  • Clinical trials
  • Novel agents
  • Recurrence
  • Targeted treatment

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Novel agents to target treatment resistance in ovarian cancer'. Together they form a unique fingerprint.

Cite this